Outcome-Based Reimbursement: The Solution to High Drug Spending?

References

• Adida E (2021) Outcome-based pricing new pharmaceuticals via rebates. Management Sci. 67(2):892–913.Google Scholar
• Anderson SP, De Palma A, Thisse JF (1992) Discrete Choice Theory of Product Differentiation (MIT Press, Cambridge, MA).Crossref, Google Scholar
• Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R (2011) Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ. Policy Law 6(3):391–403.Crossref, Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES (2005) Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J. Amer. College Cardiology 45(2):185–197.Crossref, Google Scholar
• Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clinic Proc. 86(4):304–314.Crossref, Google Scholar
• Carlson J, Garrison LP Jr, Sullivan SD (2009) Paying for outcomes: Innovative coverage and reimbursement schemes for pharmaceuticals. J. Managed Care Pharmacy 15(8):683–687.Crossref, Google Scholar
• Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ and Veenstra DL (2010) Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3):179–190.Google Scholar
• Centers for Medicare and Medicaid Services (2016) CMS proposes to test new Medicare Part B prescription drug models to improve quality of care and deliver better value for Medicare beneficiaries. Accessed April 2021, https://www.cms.gov/newsroom/press-releases/cms-proposes-test-new-medicare-part-b-prescription-drug-models-improve-quality-care-and-deliver.Google Scholar
• Centers for Medicare and Medicaid Services (2017a) Innovative treatments call for innovative payment models and arrangements. Accessed April 2021, https://www.cms.gov/newsroom/press-releases/cms-innovative-treatments-call-innovative-payment-models-and-arrangements.Google Scholar
• Centers for Medicare and Medicaid Services (2017b) National Health Expenditures 2017 Highlights. Accessed April 2018, https://www.cms.gov/newsroom/press-releases/cms-office-actuary-releases-2017-national-health-expenditures.Google Scholar
• Ching AT, Lim H (2020) A structural model of correlated learning and late-mover advantages: The case of statins. Management Sci. 66(3):1095–1123.Link, Google Scholar
• Claxton G, Rae M, Panchal N, Lundy J, Damico A, Osei-Anto A, Kenward K, Whitmore H, Pickreign J (2011) Employer Health Benefits: 2011 Annual Survey (Henry J. Kaiser Family Foundation, Menlo Park, CA; Health Research & Educational Trust, Chicago). Accessed December 2021, https://www.msbo.org/sites/default/files/8225.pdf.Google Scholar
• Coulton L, Annemans L, Javier J, Brown R, Keskinaslan A (2010) Risk-sharing schemes worldwide: A landscape analysis of health outcomes-based reimbursement agreements. ISPOR 4th Asia-Pacific Conf., Abstracts, Phuket, Thailand.Google Scholar
• Davis J, Gallego G, Topaloglu H (2013) Assortment planning under the multinomial logit model with totally unimodular constraint structures. Working paper, Columbia University, New York, NY.Google Scholar
• Erdem T, Keane MP (1996) Decision-making under uncertainty: Capturing dynamic brand choice processes in turbulent consumer goods markets. Marketing Sci. 15(1):1–20.Link, Google Scholar
• FiercePharma (2016a) Cigna inks results-based deals on pricey Amgen, Sanofi PCSK9 meds. Accessed April 2018, https://www.fiercepharma.com/pharma/cigna-inks-results-based-deals-pricey-amgen-sanofi-pcsk9-meds.Google Scholar
• FiercePharma (2016b) Lilly’s Trulicity joins pay-for-performance trend with Harvard Pilgrim deal. Accessed April 2018, https://www.fiercepharma.com/pharma/lilly-s-trulicity-joins-pay-for-performance-trend-harvard-pilgrim-deal.Google Scholar
• Food and Drug Administration (2016) Withdrawal of approval of new drug applications for Advicor and Simcor. Accessed April 2018, https://www.federalregister.gov/documents/2016/04/18/2016-08894/abbvie-inc-withdrawal-of-approval-of-new-drug-applications-for-advicor-and-simcor.Google Scholar
• Garrison LP, Towse A, Briggs A, De Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M (2013) Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation. Value Health 16(5):703–719.Crossref, Google Scholar
• Gupta D, Mehrotra M (2015) Bundled payments for healthcare services: Proposer selection and information sharing. Oper. Res. 63(4):772–788.Link, Google Scholar
• Harvard Pilgrim (2017) Harvard Pilgrim signs second groundbreaking contract with Amgen for Repatha. Accessed September 2019, https://www.harvardpilgrim.org/public/news-detail?nt=HPH_News_C&nid=1471912937208.Google Scholar
• Hoadley J, Hargrave E, Merrell K (2011) Medicare Part D formularies, 2006–2011: Update to chartbook. Report, MedPAC, Washington, DC. Accessed April 2018, http://67.59.137.244/documents/Aug11_PartDFormulariesChartbook_Updated_CONTRACTOR_ss.pdf.Google Scholar
• Hou R, Goldberg AC (2009) Lowering low-density lipoprotein cholesterol: Statins, ezetimibe, bile acid sequestrants, and combinations: Comparative efficacy and safety. Endocrinology Metabolism Clinics 38(1):79–97.Crossref, Google Scholar
• IQVIA (2019) Medicine use and spending in the U.S. Accessed December 2021, https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/medicine-use-and-spending-in-the-us---a-review-of-2018-outlook-to-2023.pdf?_=1640885282192.Google Scholar
• King GJ, Chao X, Duenyas I (2019) Who benefits when prescription drug manufacturers offer copay coupons? Management Sci. 65(8):3758–3775.Link, Google Scholar
• Kouvelis P, Xiao Y, Yang N (2015) PBM competition in pharmaceutical supply chain: Formulary design and drug pricing. Manufacturing Service Oper. Management 17(4):511–526.Link, Google Scholar
• Kouvelis P, Xiao Y, Yang N (2018) Drug pricing for competing pharmaceutical manufacturers distributing through a common PBM. Production Oper. Management 27(8):1399–1419.Google Scholar
• Kunreuther H, Hogarth R, Meszaros J (1993) Insurer ambiguity and market failure. J. Risk Uncertainty 7(1):71–87.Crossref, Google Scholar
• Loftus P (2017) Drug companies tie costs to outcomes. Wall Street Journal (September 12, 2017), accessed December 2021, https://www.wsj.com/articles/drug-companies-tie-costs-to-outcomes-1505268421.Google Scholar
• Mahjoub R, Ødegaard F, Zaric GS (2018) Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Econom. 27(1):15–25.Crossref, Google Scholar
• Medical Expenditure Panel Survey (2019) Survey background. Accessed April 2021, https://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp.Google Scholar
• Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC (2009) Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. Amer. Heart J. 157(1):195–203.Crossref, Google Scholar
• Mukherjee S (2017) Is $475,000 too high a price for Novartis’s historic cancer gene therapy? Fortune Online (August 31). Accessed December 2021, http://fortune.com/2017/08/31/novartis-kymriah-car-t-cms-price/.Google Scholar
• Nallamothu BK, Hayward RA, Bates ER (2008) Beyond the randomized clinical trial: The role of effectiveness studies in evaluating cardiovascular therapies. Circulation 118(12):1294–1303.Crossref, Google Scholar
• Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, Drago F (2015) Do the current performance-based schemes in Italy really work? “Success Fee”: A novel measure for cost-containment of drug expenditure. Value Health 18(1):131–136.Crossref, Google Scholar
• Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, Vegesna A, Wu E, Navarro RP (2017) Outcomes-based contracting experience: Research findings from US and European stakeholders. J. Managed Care Specialty Pharmacy 23(10):1018–1026.Crossref, Google Scholar
• Nordqvist C (2012) One year on herceptin for breast cancer ideal. Accessed April 2021, https://www.medicalnewstoday.com/articles/250912.Google Scholar
• Reddy S (2017) When cholesterol drugs cost $14,000, an insurance tug-of-war. The Wall Street Journal Online (June 19), accessed April 2021, https://www.wsj.com/articles/when-cholesterol-drugs-cost-14-000-an-insurance-tug-of-war-1497889667.Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, et al. (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New England J. Medicine 372(16):1500–1509.Crossref, Google Scholar
• So KC, Tang CS (2000) Modeling the impact of an outcome-oriented reimbursement policy on clinic, patients, and pharmaceutical firms. Management Sci. 46(7):875–892.Link, Google Scholar
• Talluri K, Van Ryzin G (2004) Revenue management under a general discrete choice model of consumer behavior. Management Sci. 50(1):15–33.Link, Google Scholar
• Thomas K, Ornstein C (2017) Considering the side effects of drugmakers’ money-back guarantees. The New York Times Online (July 10), accessed April 2018, https://www.nytimes.com/2017/07/10/health/prescription-drugs-cost.html.Google Scholar
• Thomas MU, Rao SS (1999) Warranty economic decision models: A summary and some suggested directions for future research. Oper. Res. 47(6):807–820.Link, Google Scholar
• Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, Aldington S, Beasley R (2007) External validity of randomised controlled trials in asthma: To whom do the results of the trials apply? Thorax 62(3):219–223.Crossref, Google Scholar
• Truong VA, Yao D (2013) Analytical models for designing pharmaceutical contracts. Working paper, Columbia University, New York, NY.Google Scholar
• Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J. Clinical Lipidology 10(3):472–489.Crossref, Google Scholar
• Xu L, Zhao H, Petruzzi NC (2021) Inducing compliance with post-market studies for drugs under FDA’s accelerated approval pathway. Manufacturing Service Oper. Management 23(1):170–190.Link, Google Scholar
• Zaric GS, O’Brien BJ (2005) Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Econom. 14(8):793–803.Crossref, Google Scholar
• Zaric GS, Xie B (2009) The impact of two pharmaceutical risk sharing agreements on pricing, promotion, and net health benefits. Value Health 12(5):838–845.Crossref, Google Scholar
• Zhang H, Zaric GS, Huang T (2011) Optimal design of a pharmaceutical price-volume agreement under asymmetric information about expected market size. Production Oper. Management 20(3):334–346.Crossref, Google Scholar
• Zorc S, Chick SE, Hasija S (2017) Outcomes-based reimbursement policies for chronic care pathways. Working paper, INSEAD.Google Scholar